Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients
- PMID: 28060118
- DOI: 10.1097/MPH.0000000000000730
Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients
Abstract
Cytomegalovirus (CMV) is a frequent complication of hematopoietic stem cell transplant in pediatric patients, with significant morbidity and mortality. Antiviral drugs are used as prophylactic, preemptive or therapeutic medicines; however, no uniform guidelines exist for the best strategy to prevent CMV disease. Resistance to standard antiviral therapies can lead to further difficulty in managing CMV disease. Studies for investigational therapies are underway and could provide options for treatment of resistant CMV, while limiting toxicities associated with currently used antiviral therapies.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
